HomeCompareCALZF vs JNJ

CALZF vs JNJ: Dividend Comparison 2026

CALZF yields 333.33% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CALZF wins by $3112.22M in total portfolio value
10 years
CALZF
CALZF
● Live price
333.33%
Share price
$0.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3112.25M
Annual income
$1,957,209,378.70
Full CALZF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CALZF vs JNJ

📍 CALZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCALZFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CALZF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CALZF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CALZF
Annual income on $10K today (after 15% tax)
$28,333.33/yr
After 10yr DRIP, annual income (after tax)
$1,663,627,971.90/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CALZF beats the other by $1,663,623,985.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CALZF + JNJ for your $10,000?

CALZF: 50%JNJ: 50%
100% JNJ50/50100% CALZF
Portfolio after 10yr
$1556.14M
Annual income
$978,607,034.05/yr
Blended yield
62.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CALZF
No analyst data
Altman Z
10.7
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CALZF buys
0
JNJ buys
0
No recent congressional trades found for CALZF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCALZFJNJ
Forward yield333.33%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$3112.25M$30.3K
Annual income after 10y$1,957,209,378.70$4,689.40
Total dividends collected$3000.20M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CALZF vs JNJ ($10,000, DRIP)

YearCALZF PortfolioCALZF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$44,033$33,333.33$10,592$272.30+$33.4KCALZF
2$184,291$137,175.49$11,289$357.73+$173.0KCALZF
3$733,748$536,556.79$12,123$472.89+$721.6KCALZF
4$2,781,635$1,996,524.01$13,141$629.86+$2.77MCALZF
5$10,050,002$7,073,652.70$14,408$846.81+$10.04MCALZF
6$34,638,543$23,885,041.43$16,021$1,151.60+$34.62MCALZF
7$114,000,322$76,937,080.16$18,122$1,588.22+$113.98MCALZF
8$358,625,914$236,645,569.53$20,930$2,228.20+$358.60MCALZF
9$1,079,474,884$695,745,156.26$24,792$3,191.91+$1079.45MCALZF
10$3,112,247,504$1,957,209,378.70$30,274$4,689.40+$3112.22MCALZF

CALZF vs JNJ: Complete Analysis 2026

CALZFStock

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Full CALZF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CALZF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CALZF vs SCHDCALZF vs JEPICALZF vs OCALZF vs KOCALZF vs MAINCALZF vs ABBVCALZF vs MRKCALZF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.